Nektar Current Deferred Revenue vs Intangible Assets Analysis

NKTR Stock

USD 1.10 0.14 14.58%

Nektar Therapeutics financial indicator trend analysis is infinitely more than just investigating Nektar Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Nektar Therapeutics is a good investment. Please check the relationship between Nektar Therapeutics Current Deferred Revenue and its Intangible Assets accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nektar Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Nektar Stock, please use our How to Invest in Nektar Therapeutics guide.

Current Deferred Revenue vs Intangible Assets

Current Deferred Revenue vs Intangible Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Nektar Therapeutics Current Deferred Revenue account and Intangible Assets. At this time, the significance of the direction appears to have strong relationship.

The correlation between Nektar Therapeutics' Current Deferred Revenue and Intangible Assets is 0.6. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Intangible Assets in the same time period over historical financial statements of Nektar Therapeutics, assuming nothing else is changed. The correlation between historical values of Nektar Therapeutics' Current Deferred Revenue and Intangible Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Nektar Therapeutics are associated (or correlated) with its Intangible Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Intangible Assets has no effect on the direction of Current Deferred Revenue i.e., Nektar Therapeutics' Current Deferred Revenue and Intangible Assets go up and down completely randomly.

Correlation Coefficient

0.6

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Intangible Assets

Non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value.

Most indicators from Nektar Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Nektar Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nektar Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in Nektar Stock, please use our How to Invest in Nektar Therapeutics guide.At this time, Nektar Therapeutics' Tax Provision is relatively stable compared to the past year. As of 01/06/2025, Sales General And Administrative To Revenue is likely to grow to 0.81, while Enterprise Value Over EBITDA is likely to drop (0.94).

	2022	2023	2024	2025 (projected)
Gross Profit	70.4M	53.5M	61.5M	58.4M
Total Revenue	92.1M	90.1M	103.6M	162.3M

Gross Profit Total Revenue

Nektar Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Current Deferred Revenue	Common Stock Total Equity	Short Term Investments	Common Stock	Net Receivables
Total Assets		0.63	0.38	0.52	0.98	0.64	0.07	-0.05	0.59	0.8	0.94	-0.22	0.99	0.44	0.17	0.47	0.45	0.5	0.52	0.99	0.49	-0.15	-0.34	0.99	-0.34	0.92
Short Long Term Debt Total	0.63		0.31	0.64	0.5	0.34	0.74	-0.02	0.18	0.33	0.64	-0.08	0.59	0.36	0.37	0.06	0.25	0.75	0.22	0.59	0.6	0.28	-0.55	0.59	-0.55	0.53
Other Current Liab	0.38	0.31		0.6	0.3	0.78	0.25	-0.21	0.58	0.28	0.27	-0.25	0.42	0.26	0.13	0.2	0.28	0.52	0.75	0.42	0.41	-0.15	-0.35	0.41	-0.35	0.45
Total Current Liabilities	0.52	0.64	0.6		0.45	0.6	0.58	0.08	0.41	0.16	0.57	-0.11	0.48	0.12	-0.19	0.13	0.12	0.51	0.49	0.48	0.97	0.09	-0.3	0.51	-0.3	0.38
Total Stockholder Equity	0.98	0.5	0.3	0.45		0.58	-0.06	0.02	0.57	0.8	0.92	-0.3	0.97	0.35	0.01	0.46	0.4	0.31	0.47	0.97	0.45	-0.22	-0.18	0.97	-0.18	0.91
Property Plant And Equipment Net	0.64	0.34	0.78	0.6	0.58		0.15	-0.19	0.72	0.39	0.57	-0.13	0.67	0.29	0.2	0.6	0.32	0.58	0.82	0.67	0.46	-0.19	-0.37	0.68	-0.37	0.65
Net Debt	0.07	0.74	0.25	0.58	-0.06	0.15		-0.03	-0.15	-0.36	0.12	-0.09	0.02	0.12	0.15	-0.08	0.0	0.52	0.1	0.03	0.56	0.32	-0.38	0.07	-0.38	-0.02
Retained Earnings	-0.05	-0.02	-0.21	0.08	0.02	-0.19	-0.03		-0.49	-0.09	0.16	0.11	-0.12	-0.87	-0.3	-0.36	-0.86	-0.2	-0.57	-0.11	0.15	0.66	0.64	-0.09	0.64	0.1
Accounts Payable	0.59	0.18	0.58	0.41	0.57	0.72	-0.15	-0.49		0.59	0.39	-0.14	0.66	0.58	0.04	0.34	0.66	0.31	0.84	0.65	0.31	-0.56	-0.33	0.64	-0.33	0.49
Cash	0.8	0.33	0.28	0.16	0.8	0.39	-0.36	-0.09	0.59		0.69	-0.18	0.82	0.4	0.21	0.25	0.43	0.29	0.33	0.82	0.09	-0.21	-0.23	0.76	-0.23	0.81
Non Current Assets Total	0.94	0.64	0.27	0.57	0.92	0.57	0.12	0.16	0.39	0.69		-0.14	0.89	0.23	0.15	0.43	0.22	0.52	0.34	0.9	0.57	0.11	-0.32	0.89	-0.32	0.87
Non Currrent Assets Other	-0.22	-0.08	-0.25	-0.11	-0.3	-0.13	-0.09	0.11	-0.14	-0.18	-0.14		-0.25	-0.18	0.39	-0.25	-0.22	0.27	-0.18	-0.25	-0.11	0.39	-0.17	-0.27	-0.17	-0.29
Cash And Short Term Investments	0.99	0.59	0.42	0.48	0.97	0.67	0.02	-0.12	0.66	0.82	0.89	-0.25		0.48	0.17	0.47	0.51	0.47	0.58	1.0	0.43	-0.24	-0.33	0.99	-0.33	0.92
Common Stock Shares Outstanding	0.44	0.36	0.26	0.12	0.35	0.29	0.12	-0.87	0.58	0.4	0.23	-0.18	0.48		0.35	0.4	0.98	0.39	0.63	0.48	0.05	-0.59	-0.72	0.45	-0.72	0.24
Non Current Liabilities Total	0.17	0.37	0.13	-0.19	0.01	0.2	0.15	-0.3	0.04	0.21	0.15	0.39	0.17	0.35		0.14	0.21	0.75	0.08	0.17	-0.33	0.32	-0.69	0.11	-0.69	0.24
Other Current Assets	0.47	0.06	0.2	0.13	0.46	0.6	-0.08	-0.36	0.34	0.25	0.43	-0.25	0.47	0.4	0.14		0.44	0.22	0.47	0.47	0.13	-0.43	-0.29	0.48	-0.29	0.41
Other Stockholder Equity	0.45	0.25	0.28	0.12	0.4	0.32	0.0	-0.86	0.66	0.43	0.22	-0.22	0.51	0.98	0.21	0.44		0.26	0.69	0.51	0.06	-0.73	-0.59	0.49	-0.59	0.26
Total Liab	0.5	0.75	0.52	0.51	0.31	0.58	0.52	-0.2	0.31	0.29	0.52	0.27	0.47	0.39	0.75	0.22	0.26		0.4	0.47	0.36	0.34	-0.81	0.44	-0.81	0.46
Property Plant And Equipment Gross	0.52	0.22	0.75	0.49	0.47	0.82	0.1	-0.57	0.84	0.33	0.34	-0.18	0.58	0.63	0.08	0.47	0.69	0.4		0.57	0.37	-0.56	-0.45	0.58	-0.45	0.45
Total Current Assets	0.99	0.59	0.42	0.48	0.97	0.67	0.03	-0.11	0.65	0.82	0.9	-0.25	1.0	0.48	0.17	0.47	0.51	0.47	0.57		0.43	-0.23	-0.33	0.99	-0.33	0.92
Short Term Debt	0.49	0.6	0.41	0.97	0.45	0.46	0.56	0.15	0.31	0.09	0.57	-0.11	0.43	0.05	-0.33	0.13	0.06	0.36	0.37	0.43		0.08	-0.19	0.47	-0.19	0.3
Current Deferred Revenue	-0.15	0.28	-0.15	0.09	-0.22	-0.19	0.32	0.66	-0.56	-0.21	0.11	0.39	-0.24	-0.59	0.32	-0.43	-0.73	0.34	-0.56	-0.23	0.08		-0.03	-0.25	-0.03	-0.04
Common Stock Total Equity	-0.34	-0.55	-0.35	-0.3	-0.18	-0.37	-0.38	0.64	-0.33	-0.23	-0.32	-0.17	-0.33	-0.72	-0.69	-0.29	-0.59	-0.81	-0.45	-0.33	-0.19	-0.03		-0.28	1.0	-0.21
Short Term Investments	0.99	0.59	0.41	0.51	0.97	0.68	0.07	-0.09	0.64	0.76	0.89	-0.27	0.99	0.45	0.11	0.48	0.49	0.44	0.58	0.99	0.47	-0.25	-0.28		-0.28	0.9
Common Stock	-0.34	-0.55	-0.35	-0.3	-0.18	-0.37	-0.38	0.64	-0.33	-0.23	-0.32	-0.17	-0.33	-0.72	-0.69	-0.29	-0.59	-0.81	-0.45	-0.33	-0.19	-0.03	1.0	-0.28		-0.21
Net Receivables	0.92	0.53	0.45	0.38	0.91	0.65	-0.02	0.1	0.49	0.81	0.87	-0.29	0.92	0.24	0.24	0.41	0.26	0.46	0.45	0.92	0.3	-0.04	-0.21	0.9	-0.21

Click cells to compare fundamentals

Nektar Therapeutics Account Relationship Matchups

Nektar Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	1.5B	1.1B	710.6M	398.0M	457.7M	707.3M
Short Long Term Debt Total	150.3M	143.2M	131.5M	117.8M	135.4M	233.4M
Other Current Liab	65.7M	40.6M	17.9M	22.2M	25.5M	26.0M
Total Current Liabilities	115.8M	85.2M	68.2M	51.3M	59.0M	88.1M
Total Stockholder Equity	1.1B	679.5M	366.6M	131.0M	150.6M	143.1M
Property Plant And Equipment Net	186.1M	177.5M	85.9M	36.9M	42.4M	40.3M
Net Debt	(48.7M)	118.0M	43.3M	82.5M	94.9M	155.3M
Retained Earnings	(2.3B)	(2.8B)	(3.2B)	(3.5B)	(3.1B)	(3.0B)
Accounts Payable	22.1M	9.7M	13.0M	9.8M	11.3M	8.3M
Cash	199.0M	25.2M	88.2M	35.3M	40.6M	71.6M
Non Current Assets Total	400.8M	321.6M	164.6M	67.3M	77.4M	73.6M
Non Currrent Assets Other	1.5M	2.7M	2.2M	4.6M	4.2M	8.3M
Cash And Short Term Investments	1.1B	734.0M	505.0M	303.6M	349.2M	437.9M
Common Stock Shares Outstanding	178.6M	183.3M	187.1M	190.0M	218.5M	229.4M
Liabilities And Stockholders Equity	1.5B	1.1B	710.6M	398.0M	457.7M	707.3M
Non Current Liabilities Total	345.7M	352.5M	275.8M	215.8M	248.1M	301.7M
Other Current Assets	21.9M	46.7M	29.2M	8.7M	10.0M	13.4M
Other Stockholder Equity	3.4B	3.5B	3.6B	3.6B	4.1B	4.4B
Total Liab	461.5M	437.7M	344.0M	267.0M	307.1M	389.8M
Property Plant And Equipment Gross	186.1M	177.5M	85.9M	123.8M	142.3M	101.3M
Total Current Assets	1.1B	795.6M	546.0M	330.7M	380.3M	476.4M
Accumulated Other Comprehensive Income	(2.3M)	(4.2M)	(6.9M)	80K	72K	75.6K
Short Term Debt	27.8M	34.9M	37.3M	19.3M	22.1M	36.6M
Current Deferred Revenue	13.9M	5.5M	91K	(8.2M)	(7.4M)	(7.0M)
Short Term Investments	862.9M	708.7M	416.8M	268.3M	308.6M	407.0M
Net Receivables	38.9M	22.5M	6.0M	2.3M	2.6M	2.5M
Other Liab	75.3M	209.3M	226.7M	162.9M	187.4M	105.7M
Other Assets	1.0M	264.6M	2.7M	2.2M	2.6M	2.5M
Property Plant Equipment	65.0M	59.7M	177.5M	85.9M	77.3M	77.9M
Inventory	15.3M	15.8M	19.2M	16.1M	18.5M	13.3M
Net Tangible Assets	1.3B	1.0B	603.0M	290.1M	333.7M	431.0M
Retained Earnings Total Equity	(1.4B)	(1.9B)	(2.3B)	(2.8B)	(2.5B)	(2.7B)
Capital Surpluse	3.1B	3.3B	3.4B	3.5B	4.0B	2.6B
Capital Lease Obligations	150.3M	143.2M	131.5M	117.8M	135.4M	74.0M

Pair Trading with Nektar Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nektar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nektar Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Nektar Stock

0.87	DNLI	Denali Therapeutics	Pair Corr
0.63	EVOK	Evoke Pharma	Pair Corr
0.82	FOLD	Amicus Therapeutics	Pair Corr
0.87	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr

Moving against Nektar Stock

0.77	LFCR	Lifecore Biomedical	Pair Corr
0.66	BMY	Bristol Myers Squibb	Pair Corr
0.48	GILD	Gilead Sciences	Pair Corr
0.4	IMCC	Im Cannabis Corp	Pair Corr

The ability to find closely correlated positions to Nektar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nektar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nektar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nektar Therapeutics to buy it.

The correlation of Nektar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nektar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nektar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Nektar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Nektar Stock Analysis

When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC